A drug-pricing plan unveiled by the Trump administration has put the U.S. on a path toward policies like those in Europe, where governments use tight cost controls.
Under the proposal, announced at an event at the Department of Health and Human Services on Thursday, President Donald Trump and health secretary Alex Azar said the administration would create a reference price for high-cost medicines paid for by Medicare, based on comparable prices from other countries.
Trump "wants the kind of discounts that are applied in Germany and the Netherlands, for the reference reimbursement prices to be applied in the U.S.," said Rodrigo Moreno-Serra, associate professor of global health economics at the University of York in England.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.